The treatment of resistant schizophrenia: a pilot, open study on the treatment with risperidone and clozapine.

This authoritative volume brings together leading experts in the field of schizophrenia to review recent progress and present informative studies on the epidemiology, genetics, neuropathology and neurochemistry of the disease. It offers readers a wealth of new information including reports on the clinical outcome and treatment of this distressing illness. Several pharmaceutical approaches are discussed concerning the efficacy of typical neuroleptics and the safer profile of the newly available atypical antipsychotic drugs. The impact of this disease on the public health system is also considered with attention focused on the cost/benefit issues and quality of life. Contributors to the volume have attempted to sensitize public opinion about the disease and to reinforce awareness for early recognition, treatment and research. It will be a valuable tool not only to pharmacologists, psychiatrists and psychologists and those in health authorities but also to marketing representatives in the pharmaceutical industry.